RN Fairey

Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy [see comments]

DE Reece, JM Connors, JJ Spinelli et al. · Blood · 1994 · 217 citations · Full text

Medicine, Oncology, Pharmacology +17

Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988

Andreas Lohri, Michael Barnett, RN Fairey et al. · Blood · 1991 · 129 citations · Full text

Medicine, Oncology, Cancer Epidemiology +12

High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy

DE Reece, MJ Barnett, JD Shepherd et al. · Blood · 1995 · 122 citations

Medicine, Oncology, Pharmacology +12

Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin’s disease

DE Reece, TJ Nevill, Antoine Sayegh et al. · Bone Marrow Transplantation · 1999 · 33 citations

Medicine, Oncology, Pharmacology +16

Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988

Andreas Lohri, Michael Barnett, RN Fairey et al. · Blood · 1991 · 13 citations · Full text

Medicine, Oncology, Cancer Epidemiology +12